insights_auto
Why is PTCT up 3.42%?
Dive Deeperchevron_right
PTCT:NASDAQ
PTC Therapeutics, Inc.
$64.70
arrow_upward
+3.42%(+2.14) 1D
$64.70
0.00% (0.00)
bedtimeAfter hours
Closed: Oct 9, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for PTCT...
Open
$62.52
High
$64.73
Low
$62.20
Mkt. cap
5.40B
Avg. vol.
1.15M
Volume
1.17M
52-wk high
$90.86
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
Open
$62.52
High
$64.73
Low
$62.20
Mkt. cap
5.40B
Avg. vol.
1.15M
Volume
1.17M
52-wk high
$90.86
52-wk low
$61.23
EPS
-$0.56
Beta
0.49
Shares outstanding
83.46M
No. of employees
991
News stories
From web sources and news partners
MarketBeat
·
31 minutes ago
PTC Therapeutics (NASDAQ:PTCT) Director Sells 2,500 Shares of Company Stock
Investing.com
·
1 hour ago
PTC Therapeutics director Michael Schmertzler sells $158k in shares
Investing.com India
·
1 hour ago
Form 4 PTC Therapeutics Inc For: 9 October By Investing.com
Stock Titan
·
2 hours ago
Under a trading plan, Section Six sells 2,500 PTC Therapeutics (PTCT) shares.
Profile
PTC Therapeutics, Inc. is a US pharmaceutical company focused on the development of orally administered small molecule drugs and gene therapy which regulate gene expression by targeting post-transcriptional control mechanisms in orphan diseases.
In September 2009, PTC entered into an agreement with Roche for the development of orally bioavailable small molecules for central nervous system diseases. PTC acquired the Bio-e platform in 2019. Wikipedia
About PTC Therapeutics, Inc.
CEOMatthew B. Klein
Employees991
FoundedJan 1, 1998
HeadquartersWarren, New Jersey, United States
SectorBiotechnology
Websiteptcbio.com